Curative Ventures | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Curative Ventures/Activity

Curative Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company Instil Bio announced a license and collaboration agreement with ImmuneOnco Biopharma for two bispecific antibody candidates.

Instil Bio

Instil Bio Curative Ventures

curativeventures.comAUG 1, 2024

AUG 1, 2024

Exit

Portfolio company Instil Bio closed its IPO with full exercise of the underwriters' option to purchase additional shares.

Instil Bio

Instil Bio Curative Ventures

curativeventures.comMAR 23, 2021

MAR 23, 2021

Exit

Portfolio company Peloton Therapeutics was acquired by Merck for up to $2.2B, bolstering its oncology pipeline.

Peloton Therapeutics

Peloton Therapeutics Curative Ventures

curativeventures.comMAY 12, 2019

MAY 12, 2019

Investment

Peloton Therapeutics secured $150M in Series E financing.

Peloton Therapeutics

Peloton Therapeutics Curative Ventures

curativeventures.comFEB 14, 2019

FEB 14, 2019

Exit

Portfolio company TCR2 Therapeutics priced its IPO of 5 million shares at $15.00/share.

TCR2 Therapeutics

TCR2 Therapeutics Curative Ventures

curativeventures.comFEB 13, 2019

FEB 13, 2019

Exit

Portfolio company CoStim Pharmaceuticals was acquired by Novartis for up to $248M.

CoStim Pharmaceuticals

CoStim Pharmaceuticals Curative Ventures

fiercebiotech.comFEB 2014

FEB 2014